Related Experiment Video
Updated: Nov 10, 2025
Utilizing High Resolution Ultrasound to Monitor Tumor Onset and Growth in Genetically Engineered Pancreatic Cancer Models
Published on: April 7, 2018
Endoscopic Ultrasound-Guided Sampling for Personalized Pancreatic Cancer Treatment
Eisuke Iwasaki1, Seiichiro Fukuhara2, Masayasu Horibe1
1Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine 35, Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan.
Abstract:
Pancreatic cancer is the most lethal solid malignancy, and the number of patients with pancreatic cancer is increasing. Systemic chemotherapies are often ineffective for such patients, and there is an urgent need for personalized medicine. Unlike other types of cancer, personalized treatments for pancreatic cancer are still in development. Consequently, pancreatic cancer is less sensitive to anticancer drugs and is often refractory to common treatments. Therefore, advances in personalized medicine for pancreatic cancer are necessary. This review examined advances in personalized medicine for pancreatic cancer, including the use of endoscopic ultrasound (EUS)-guided sampling. EUS-guided sampling is widely used for diagnosing pancreatic tumors and is expected to be applied to sampled tissues. Additionally, there has been an increase in clinical research using EUS-guided sampling. The combination of precision medicine using genomic testing and pharmacological profiles based on high-throughput drug sensitivity testing using patient-derived organoids is expected to revolutionize pancreatic cancer treatment.
Insights
Personalized medicine, including endoscopic ultrasound-guided sampling and genomic testing, offers new hope for treating pancreatic cancer, a lethal malignancy with limited treatment options.
Area of Science:
- Oncology
- Gastroenterology
- Precision Medicine
Background:
- Pancreatic cancer is a highly lethal malignancy with increasing incidence.
- Current systemic chemotherapies are often ineffective, highlighting the need for novel treatments.
- Personalized medicine approaches for pancreatic cancer are still under development.
Purpose of the Study:
- To review advances in personalized medicine for pancreatic cancer.
- To explore the role of endoscopic ultrasound (EUS)-guided sampling in personalized treatment strategies.
- To discuss the potential of integrating genomic testing and drug sensitivity profiling for improved patient outcomes.
Main Methods:
- Review of current literature on pancreatic cancer treatment and personalized medicine.
- Examination of the application of endoscopic ultrasound (EUS)-guided sampling in diagnostics and tissue acquisition.
- Analysis of high-throughput drug sensitivity testing using patient-derived organoids.
Main Results:
- Endoscopic ultrasound (EUS)-guided sampling is a valuable tool for pancreatic tumor diagnosis and tissue collection.
- Clinical research utilizing EUS-guided sampling for pancreatic cancer is expanding.
- Genomic testing and organoid-based drug sensitivity profiling show promise for personalized treatment.
Conclusions:
- Advances in personalized medicine, particularly EUS-guided sampling and precision oncology, are crucial for improving pancreatic cancer outcomes.
- Integrating genomic data with pharmacological profiles from patient-derived organoids is expected to revolutionize pancreatic cancer treatment.
- Further research and clinical application of these personalized approaches are necessary to combat this lethal disease.
